FREE patent keyword monitoring and additional FREE benefits. /images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
Fresh Patents
Monitor Patents Patent Organizer How to File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations


Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Oxygen Containing Hetero Ring > The Hetero Ring Is Five-membered > Chalcogen Bonded Directly To The Hetero Ring

Chalcogen Bonded Directly To The Hetero Ring

Chalcogen Bonded Directly To The Hetero Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/24/06 - 20060189684 - 3-phenylfuran-2-one derivatives as cox-2 inhibitor
The present invention relates to 3-phenylfuran-2-ones of formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses. ...

05/18/06 - 20060106098 - Andrographolide and its derivatives as tnf-alpha antagonists
Andrographolide and its derivatives represented by general formula (I) defined above are useful as TNFα (tumor necrosis factor alpha) antagonists or inhibitors which have inhibitory effect on the binding of TNFα to TNF-RI. Andrographolide exhibited inhibitor activity with IC50 values 60 μM on L929 cell proliferation/cytotoxicity assay without cell cytotoxicity. ...

03/23/06 - 20060063831 - Composition of labdane diterpenes extracted from andrographis paniculata, ufeful for the treatment of autoimmune diseases, and alzheimer disease by activation for ppr-gamma receptors
inhibits the synthesis of pro-inflammatory cytokines, activates the PPAR-gamma receptor and diminishes nuclear factor kappa B. The compound is useful to treat auto-immune diseases, for organ and tissue transplantation, and to treat immunodeficiency (e.g., AIDS). ...

10/27/05 - 20050239877 - Synthetic lactone formulations and method of use
Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when ...

10/06/05 - 20050222251 - Dual inhibition of cyclooxygenase-2 and carbonic anhydrase
Compounds of Formula I potently inhibit both cyclooxygenase-2 and carbonic anhydrases. Inhibition of carbonic anhydrases by a cyclooxygenase-2 inhibitor may affect significantly the safety and efficacy profiles of such a dual inhibitor in the treatment of cyclooxygenase-2 mediated disorders, compared to a cyclooxygenase-2 inhibitor without carbonic anhydrase inhibitory activity. ...

09/29/05 - 20050215628 - Andrographolide and analogues as inhibitors of tnfalpha and il-1beta expression
wherein R1 and R2 are defined herein. It also relates to is a method of treating inflammatory bowel disease with such a compound. ...

08/11/05 - 20050176814 - Deuterated substituted dihydrofuranones and medicaments containing these compounds
The invention concerns deuterated substituted dihydrofuranones and pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated substituted dihydrofuranones for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea. In addition, the invention discloses pharmaceutical compositions, which contain ...

06/30/05 - 20050143453 - Selective preventing and therapeutic agents for progressive lesion after organic damage
An object of the present invention is to provide a pharmaceutical agents for preventing and/or treating the progressive lesion after the organic damage without inhibiting organic function or regeneration function thereof, by selectively suppressing the induction of cytotoxic effector macrophages which are induced into the damaged organs in response to ...



###

FreshPatents.com Support